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Human immunodeﬁciency virus (HIV), the cause of acquired immu-
nodeﬁciency syndrome (AIDS), has been a major global public health
issue for decades. Approximately 35.0 million people were infected
with HIV at the end of 2013 globally (http://www.who.int/
mediacentre/factsheets/fs360/en/). Although aggressive treatment reg-
imens using highly active antiretroviral therapy (HAART) is successful
in suppressing HIV viral replication and the progression of HIV disease,
the persistence of virus within latently infected cells enables viral re-
bound to occur once antiretroviral treatment is terminated (Chun
et al., 1995). The association of many of the currently available antire-
troviral agents with adverse side-effects dictates the need for continu-
ing efforts to identify other antiretroviral targets and therapies.
Interferon (IFN), a key component of human innate immunity
against invading pathogens acts by inducing expression of hundreds
of IFN-stimulated genes (ISGs). Several HIV-1 restriction factors suchUniversity, Changchun, Jilin
jhu.edu (X.-F. Yu).
pen access article under the CC BY-Nas APOBEC3G, BST-2 and SAMHD1 can be stimulated by IFN (Malim
and Bieniasz, 2012) but none of them account for the strong IFN-
mediated suppression of HIV-1. Recently, human myxovirus-
resistance protein B (MxB) has been identiﬁed as a major inhibitor of
HIV-1 replication induced by IFN (Kane et al., 2013, Goujon et al.,
2013, Liu et al., 2013).
Like mostmammals, humans carry twomyxovirus resistance genes,
MX1 and MX2, which have arisen by gene duplication (Horisberger
et al., 1983, Aebi et al., 1989) and encode the interferon-inducible
dynamin-like GTPases MxA and MxB (Aebi et al., 1989). Human MxA
has been shown to suppress a wide range of pathogenic DNA and RNA
viruses (Gordien et al., 2001). In contrast, human MxB does not sup-
press the viruses tested in previous studies (Melen et al. 1996). MxB in-
hibits HIV-1 replication at post-entry steps (Schulte et al., 2015, Buffone
et al., 2015, Fackler and Keppler, 2013, Liu et al., 2013, Kane et al., 2013,
Goujon et al., 2013, Goujon et al., 2015, Goujon et al., 2014). MxB bind-
ing to HIV-1 capsid (CA) has been shown to be important for viral re-
striction (Fribourgh et al., 2014, Fricke et al., 2014, Kong et al., 2014).
Unlike APOBEC3, BST-2 and SAMHD1, MxB have not been found to
be antagonized by HIV or SIV encoded regulatory proteins. Whether
MxB antiviral activity plays an important role in vivo and whether
HIV-1 can develop mechanisms to escape MxB activity during viralC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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identiﬁed a number of capsid variants that render the virus resistant
to the activity of MxB. These MxB resistant capsid variants do not alter
viral ﬁtness and can still be recognized by MxB. Some of the identiﬁed
variants are most commonly found in subtype C HIV-1 and are accumu-
lating during expansion of the subtype C epidemic.
2. Materials and Methods
2.1. Ethics Statement
Whole blood was obtained from healthy donors that signed an in-
formed consent. This study has been approved by the Ethics Committee
of Institute of Virology and AIDS Research, First Hospital of Jilin
University.
2.2. Plasmid Construction
The HIV-1-based expression vector pSCRPSY-MxB was a generous
gift from Dr. Paul D. Bieniasz (The Rockefeller University). The MxB ex-
pression plasmid Retro-X-MxB and shRNA (TRCN0000056713)
targeting MxB were generous gifts from Dr. Chen Liang (McGill Univer-
sity). To generate an expression vector encoding HA-taggedMxB fusion
protein, theMxB-HA fragmentwas PCR ampliﬁed using Retro-X-MxB as
the template, it was then digested with SalI and XbaI and cloned into
VR1012 to generate pVR1012-MxB-HA. Plasmids were generated
encoding MxB with an N-terminal truncation: MxB(Δ1–82). This trun-
cated protein was fused with HIV-1 core binding motif sequences de-
rived from PDZD8(MxB(Δ1–82)-sPDZD8), which was constructed by
Generay Biotech (Shanghai). The HIV-1 GFP reporting vector (pNL4-3-
ΔEnv-EGFP, Cat# 11,100) provided by Dr. Robert Siliciano (Johns Hop-
kins University) was obtained through the NIH AIDS Research and Ref-
erence Reagent Program, NIH. HIV-1 NL4-3 ΔEnv-GFP with capsid
mutants was provided by Dr. Christopher Aiken (Vanderbilt University
School of Medicine). The NL4-3 CA G116A infectious clonewas generat-
ed by replacing the BssHII-SpeI DNA fragment from NL4-3 (Cat#114,
provided byDr.MalcolmMartin and obtained through theNIH AIDS Re-
agent Program, Division of AIDS, NIAID, NIH) with that from NL4-3
ΔEnv-GFP (G116A). The composition of the NL4-3 CA G116A construct
was conﬁrmed by DNA sequencing.
2.3. Cells
HEK293T cells (AIDS Research and Reference Reagents Program, Cat
#3522) and TZM-bl cells (AIDS Research and Reference Reagents Pro-
gram, Cat#8129)weremaintained in Dulbecco'smodiﬁed Eagle'smedi-
um (DMEM, Life Technology) with 10% fetal bovine serum (FBS) and
penicillin-streptomycin. The cell lines U937 and K562 (ATCC)were pro-
vided by Dr. Donald Small (Johns Hopkins University) and cultured in
RPMI medium with 10% FBS. SupT1 cells were grown in RPMI medium
supplemented with 10%FBS. Peripheral blood mononuclear cells
(PBMC)were obtained frombuffy-coat by Ficoll density gradient centri-
fugation. Monocytes enriched from PBMC by positive selection using
CD14 MicroBeads were differentiated into macrophages by culturing
in RPMI supplemented with 10% FBS, 50 ng/ml human GM-CSF (R&D
Systems) 100 U/ml penicillin, and 100 μg/ml streptomycin. shRNA-
silenced cell lines were generated according to the manufacturer's in-
structions (Open biosystem) and selected for resistance to puromycin.
All cultured cell lines were maintained at 37 °C in a humidiﬁed atmo-
sphere containing 5% CO2.
2.4. Transfection and Immunoblotting
DNA transfection was carried out using Lipofectamine 2000
(Invitrogen) according to the manufacturer's instructions. HEK293T
cells were harvested at 48 h after transfection, washed twice with coldPBS, and lysed in lysis buffer (150 mM Tris, pH 7.5, with 150 mM
NaCl, 1% Triton X-100, and complete protease inhibitor cocktail tablets
[Roche]) at 4 °C for 30 min, then centrifuged at 10,000g for 30 min.
The materials were then analyzed by SDS-PAGE and immunoblotting
with the appropriate antibodies as previously described (Wei et al.,
2012). The following antibodies were used: anti-MxB (Novus Biologi-
cals, NBP1-81018), anti-Cyclophilin A (Santa Cruz Biotechology, sc-
134,310), anti-HA (Covance, MMS-101R-1000), and anti-β-actin MAb
(Sigma, A3853). Monoclonal antibody anti-CAp24 (Cat #1513) was ob-
tained from the AIDS Research and Reference Reagents Program.
2.5. Viruses and Infection
For HIV-1GFP viral production, HEK293T cells were transfectedwith
9 μg of HIV-1ΔENV-GFP and 3 μg of pCMV-VSV-G encoding plasmids;
for shRNA production, HEK293T cells were transfected with 5 μg of
the shRNA construct, 5 μg of the packaging plasmid pΔ8.91, and 2μg
of the VSV-G encoding plasmid. Medium was harvested 48h later,
then ﬁltered at 0.45 μm. Supernatants were then puriﬁed, and lentivirus
was concentrated by ultracentriﬁgation at 28 K for 1.5 h with a 20% su-
crose cushion. The virus pellet was then dissolved in PBS and stored at
−80 °C. For single infections with the HIV-1-GFP virus, U937, K562, or
293T cells were plated in 24-well plates 12 h before infection, and the
efﬁciency of productive infection was analyzed 48 h later by ﬂow cy-
tometry (FACSCalibur, BD Biosciences). For Transmitted/founder (T/F)
of HIV-1 (ZM249M) infection, viruses were generated from transfected
HEK293T cells. SupT1 or MxB-SupT1 cells were exposed to equal
amount of ZM249M HIV-1 for 2 h and the supernatants were replaced
by fresh media. Two days later, the amount of virus that was released
into the culture supernatantwasdetermined by infecting the TZM-bl in-
dicator cells. All results are representative of more than three indepen-
dent experiments.
2.6. Viral Replication Assay
Primary PBMC were separated from whole blood of healthy donors
using the Ficoll-Hypaque method. CD4+ cells were isolated using CD4
MicroBeads (Miltenyi, Bergisch Gladbach, Germany). Cells were then
cultured in RPMI 1640 medium containing 5 μg/ml PHA and 20 IU/ml
human recombinant IL2 for 3 days. HIV-1 NL4-3 and NL4-3 CA G116A
viruses were generated by transfecting HEK293T cells. Virus stocks
were assessed for CAp24 concentration using an HIV-1 p24 ELISA
Assay kit (XpressBio, Frederick, MD). Equal amounts of virus were
used to infect activated T cells and infected cells were washed 6 h
after infection. Quantitation of newly produced virus in the superna-
tants of infected cultureswas determined by CAp24 ELISA and a viral in-
fectivity assay using TZM-bl cells. Viruses in the supernatants were
harvested at 2, 4, and 8 days post infection and determined using the
CAp24 ELISA assay. The infectivity of newly produced viruses was
assessed by using the same volume of supernatants to infect the indica-
tor TZM-bl cells. Brieﬂy, 2 × 104 TZM-bl cellswere placed in 96-well cul-
ture plates and cultured overnight. The cells were infected with 50 μl
supernatants containing NL4-3 or NL4-3 CA G116A viruses. After 48 h
incubation at 37 °C with 5% CO2, luciferase activity in cell lysates was
measured using the Luciferase Assay kit (Promega, Madison, WI).
2.7. Quantitative Real-time PCR
Cells were collected at 24 h post-infection and washed with PBS.
Total RNA was extracted from cells by TRIzol (Invitrogen) and cDNA
sampleswere generated by using theHigh Capacity cDNAReverse Tran-
scription Kit (Invitrogen) according to the manufacturer's instruction.
Sampleswere then analyzed by quantitative PCRusing FastStart Univer-
sal SYBR Green Master Mix (Roche) and the ABI 7000 sequence detec-
tion system (Applied Biosystems). The sequences of DNA primers for
real-time PCR are as follows: Human IFN-β, sense: AGGACAGGATGA
Fig. 1. The intrinsic features of the HIV-1 core that critically affect sensitivity to MxB restriction. (A) Table of HIV-1 capsid variants which alter viral core stability (either decreased or
increased) or have no effect (wild type-like). (B) Location of indicated CA mutations on the structural model of the CA monomer (PDB: 3GV2). (C) Folds of restriction to of indicated
HIV-1 infectivity by MxB in the presence or absence of MxB expression in K562 cells. The infectivity was measured 48 h after viral infection by using ﬂow cytometry to detect GFP
positive cells. Results are representative of four independent experiments. Each bar is the average of three replicates from the same experiment (error bars indicate standard
deviations). (D) Relative infectivity of HIV-1 containing the indicated capsid mutants in Hela cells. (E) Location of amino acid residues important for HIV-1 resistance to MxB on the
structural model of the CA monomer (PDB: 3GV2). (F) Relative infectivity of HIV-1 containing CA mutants H87P, G116 A or P207A in the presence or absence of MxB expression in
K562 cells. The infectivity was measured 48 h after viral infection using ﬂow cytometry to detect GFP positive cells. Results are representative of four independent experiments. Each
bar is the average of three replicates from the same experiment (error bars indicate standard deviations). The p values were calculated using ANOVA test. (G) Relative infectivity of
HIV-1 with the indicated CA mutants compared to the infectivity of the same quantity of wild type virus. The viruses were generated by transfecting HEK293T cells. The same quantity
of each virus, measured by viral mRNA, was used to infect the Hela cells. (H) IFN-β mRNA induction after HIV-1 infection in the presence or absence of AZT. Monocyte-derived
macrophages isolated from healthy donors were challenged with HIV-1 wild-type viruses, viruses containing MxB-resistant CA mutations (H87P, or G116A, or P207A), or the CypA
binding- defective mutant G89V, respectively. The ﬁgure shows the effect of CA mutations on IFN-βmRNA expression in macrophages after infection with HIV-1 viruses containing the
indicated CA mutations. Cells were harvested 24 h after infection for total RNA extraction, cDNA generation and quantitation by RT-PCR assay. mRNA of interferon beta (IFN-β) was
normalized by expression of human GAPDH mRNA.
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sense: ATGACATCAAGAAGGTGGTG, anti-sense: CATACCAGGAAATGAG
CTTG.
2.8. Step Gradient Analyses
For step sucrose gradient analysis, 2 × 106 MxB-K562 cells were
harvested and resuspended in lysis buffer (10 mM Tris, pH 7.4,
1.5 mM MgCl2, 10 mM KCl, and 0.5 mM DTT). Cells were frozen and
thawed twice. Cell lysates were centrifuged at 11,000g for 10 min.
The supernatant was collected and immediately used in the binding
assay. Puriﬁed virus was dissolved in PBS buffer, exposed brieﬂy to
0.1% Triton X-100, and loaded onto soluble MxB containing cell lysates
and step sucrose gradient as previously described (Shah and Aiken,
2011). Three fractions were harvested: one containing soluble proteins
(F1), a buffer fraction (F2), and the virus-core containing fraction (F3).
The individual gradient fractions were then subjected to immunoblot
analysis.
2.9. Statistical Analysis
Differences among test groups were analyzed by an ANOVA test
(Stata Corp, College Station, TX). A value of p b 0.05 was considered to
be signiﬁcant.3. Results
3.1. Naturally Occurring Capsid Variants That Do Not Reduce Viral Fitness
Render HIV-1 Resistant to the Inhibition of MxB
We screened a number of CA variants with single amino acid substi-
tutions that have been shown to decrease (P38A, Q63A/Q67A) or in-
crease (E45A) HIV-1 core stability or to alter host factor binding
(G89V) to theHIV-1 core (Shah et al., 2013, Forshey et al., 2002).Weob-
served that certain CA mutations could indeed make mutant HIV-1 re-
sistant to MxB mediated inhibition (Fig. 1). These HIV-1 variants can
be separated into three classes: (1) resistant to MxB but with reduced
viral infectivity (P38A, Q63A/Q67A) (Fig. 1a–d); (2) resistant to MxB
with normal infectivity but enhanced ability to trigger interferon pro-
duction (CA-G89V) (Fig. S1 and Fig. 1h); and (3) resistant to MxB
with normal infectivity and unaltered ability to trigger interferon pro-
duction at a level similar to that seen with WT HIV-1 (Fig. 1e–h).
Interestingly, we identiﬁed three CA surface mutants (H87P, G116A,
P207A) that could signiﬁcantly restore viral infection levels even in the
presence of MxB expression (Fig. 1f). By investigating the effects of
these capsid mutants on the HIV-1 life cycle, we conﬁrmed that these
capsid mutants maintained similar viral infectivity as wild type HIV-1
(Fig. 1g). cDNA encoding capsid generated during reverse transcription
of viral RNA can potentially interact with host cell proteins and trigger
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encoding the G89V capsid mutant does not binds host CypA resulting
in immune activation that prevents viral replication. The CA mutants
we have generated did not trigger such immune activation in primary
monocyte-derived macrophages (Fig. 1h).
To investigate the infectivity of HIV-1 viruses containing these MxB-
resistance CA mutations in interferon (IFN)-treated primary macro-
phages, we isolatedmacrophages fromhealthy donors as previously de-
scribed (Yu et al., 1991). IFN pre-treated and untreated cells were
challenged with equal amounts of the indicated GFP-reporter viruses.
48 h after infection, GFP positive cells were analyzed using ﬂow cytom-
etry. HIV-1mutants (H87P, G116A, P207A) maintained similar infectiv-
ity to wild-type virus in primary macrophages (Fig. 2a). As expected,
interferon treatment signiﬁcantly increased MxB expression in primary
macrophages (Fig. 2b). More importantly, these MxB resistant viruses
(H87P, G116A, P207A) became more resistant (2.64–3.40 fold) to
interferon-mediated anti-viral activity than the wild-type HIV-1 virus
in primary macrophages (Fig. 2a).
Transmitted/founder (T/F) of HIV-1 subtype C ZM249M containing
the G116A mutation was also evaluated for MxB sensitivity. Similar in-
fectivity was detected for NL4-3 and ZM249M viruses in K562 cells
(Fig. 2c). Compared to NL4-3 virus, ZM249M virus was more resistant
to MxB-mediated viral inhibition in MxB transduced SupT1 cells
(Fig. 2c). In addition, the virus replication assay conﬁrmed that HIV-1
NL4-3 CA G116Amaintained a replication capacity similar to the paren-
tal NL4-3 virus in primary T cells (Fig.S1). Together, these data indicate
that the G116A mutation in CA can reduce HIV-1 sensitivity to MxB
restriction.
3.2. MXB Resistant Capsid Variations Are Detected Among Primary HIV-1
Isolates
HIV-1 variants (H87P, G116A, P207A) were less sensitive to MxB
and still maintained viral infectivity. More importantly, these HIV-1Fig. 2.Certain CAp24 variants conferHIV-1 resisitance toMxB. (a) CAp24mutations renderHIV-
infection, macrophages were cultured with or without 500 U ml−1 IFN-α. Treated cells were c
(H87P, or G116A, or P207A) respectively. The infectivity was measured 48 h after viral infec
three independent experiments. The p values were calculated using ANOVA test with the Bon
immunoblotting using the indicated antibodies (b). (c) Transmitted/founder (T/F) of HIV-1
control SupT1 and MxB expressing SupT1 cells. Levels of HIV-1 replication were determined b
the amount of HIV-1 produced from MxB- SupT1 cells by that from control SupT1 cells. Resul
replicates from the same experiment (error bars indicate standard deviations). The p values wvariants carrying MxB-resistance mutations could be detected
among primary HIV-1 isolates from different subtypes. For example,
the 2013 HIV sequence compendium reveals that A116 variants are
detected among subtypes A, C, and D, which are prevalent in Africa
and Asia as well subtype B which is the prevalent strain in Europe
and North America. In fact, in subtype C, the A116 variant is the dom-
inant genotype (Fig. 3a). The accumulation of P87 and A207 variants
among HIV-1 subtypes A, B, C and D was also detected but less prev-
alent than A116 (Fig. S2).
To further evaluate the accumulation of MxB-resistance mutations
during HIV-1 transmission in human populations, we analyzed the se-
quences of circulating HIV-1 stains collected in China since the begin-
ning of the epidemic (1997–2010). A unique subtype B/C
recombinant (CRF08) was generated in Yunnan Province
(McClutchan et al., 2002, Yu et al., 1998, Piyasirisilp et al., 2000).
This recombinant arose from HIV-1 subtype B from Myanmar and
subtype C from India in association with drug trafﬁcking patterns be-
tween those two countries (Beyrer et al., 2000). The majority of the
gag gene of CRF08 is subtype C but contains a fragment of CA gene
from subtype B (Fig. S3). CRF08 was then transmitted to the neigh-
boring Guangxi Province from Yunnan Province in 1997. The Guangxi
founder CRF08 viruses in 1997 all carried the G116 genotype (Fig. 3b).
However, 55% of the circulating CRF08-BC strains detected in 2010
carried the A116 genotype and the G116 viral strains decreased to
40% (Fig. 3b).
Accumulation of MxB resistance mutations at position 207 of CA
during HIV-1 transmission in Southern China was observed (Fig. S4).
While the parental subtypes B, C and original CRF08 BC recombinant
HIV-1 strains all contained the MxB-sensitive P207 genotype, more re-
cent CRF08 BC recombinant HIV-1 strains carried the A207 MxB-
resistant genotype (Fig. S4). Similar accumulation of CA mutation at
position 208, which was identiﬁed in a recent report (Liu et al.,
2015), was also observed (Fig. S5). These ﬁndings all suggest possible
selection for MxB resistant HIV-1 variants.1 partially insensitive to inhibition by Interferon in primarymacrophages. 24 h before viral
hallenged by HIV-1 wild-type viruses or viruses containing MxB-resistance CA mutations
tion by using ﬂow cytometry to detect GFP positive cells. Results are representative of
ferroni correction. The expression of endogenous MxB in macrophages was detected by
subtype C resistant to MxB. Transmitted/founder virus (ZM249M) was used to infect
y infecting the TZM-bl reporter cells. Fold-inhibition by MxB was calculated by dividing
ts are representative of three independent experiments. Each bar is the average of three
ere calculated using ANOVA test with the Bonferroni correction.
Fig. 3.Detection ofMxB resistant CAvariations amongprimaryHIV-1 strains fromdifferent subtypes. (a) The distribution of CA116 variants in globalHIV-1 groupMsubtypes A, B, C andD.
(b) Paths (arrows) of HIV-1 transmission to and within China. The HIV-1 B/C recombinant CRF08 was generated in Yunnan Province due to recombination between subtype B from
Myanmar and subtype C from India. CRF08 was subsequently transmitted to Guangxi Province. The pie charts show the proportion of viral capsid variants at amino acid 116 in south
China, colored in red (G116), purple (A116) and brown (others).
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out Affecting Capsid Binding
MxB has been shown to recognize HIV-1 capsid and this interaction
is important for MxB-mediated HIV-1 inhibition (Fribourgh et al., 2014,
Kong et al., 2014, Fricke et al., 2014, Matreyek et al., 2014). Surprisingly,
amino acid variations at positions 87, 116 and 207 of CA inﬂuenced the
sensitivity of these mutant HIV-1 to MxB activity but did not enhance
the interaction of themutant corewithMxB (Fig. 4).We next used a dif-
ferent CA-MxB binding assay recently reported by others to investigate
the interaction between CAp24 (WT and mutants) and MxB (Liu et al.,
2015). All tested CAp24 variants maintained MxB binding (Fig.S6). De-
letion of the amino-terminal region ofMxB (MxBΔ1–82) resulted in re-
duced HIV-1 core binding and impaired ability to inhibit HIV-1
(Fig. S7A–C). Addition of a CA binding motif from PDZD8 (Guth and
Sodroski, 2014, Henning et al., 2010) restored HIV-1 core binding but
could not enhance the anti-HIV activity of chimeric MxB (Δ1–82)-
PDZD8 (Fig. S7B, C). HIV-1 CAmutants lacking CypA interaction became
resistant to MxB restriction (Liu et al., 2013, Kane et al., 2013, Goujon
et al., 2013, Busnadiego et al., 2014) but these mutations had no effect
on MxB binding (Liu et al., 2015, Fricke et al., 2014). CsA treatment
which disrupts CyPA and CA interaction also impaired MxB mediated
HIV-1 inhibition (Fig. S8).
HIV-2 is less sensitive to MxB mediated restriction (Fricke et al.,
2014, Goujon et al., 2013) and its CA is known to interact poorly with
CypA (Lahaye et al., 2013). Interestingly, enhancement of CypA bindingFig. 4. Capsids of HIV-1 variants resistant toMxB inhibition still interact withMxB. (A) Schemati
mixedwith solubleMxB containing cell lysates and subsequently loaded onto step sucrose gradi
associated MxB (F3) were subjected to immunoblot analysis. Antibodies against HIV-1 CAp24to HIV-2 CA (Lahaye et al., 2013) (Fig. S9A, B) did not increase HIV-2
sensitivity to MxBmediated restriction (Fig. S9C). These data again sug-
gest that MxB binding to HIV-1 CA is necessary but not sufﬁcient for
MxB-mediated restriction.
It has been reported that U937 cells express signiﬁcant level of en-
dogenous MxB proteins but do not suppress HIV-1 infection even in
the presence of interferon (Kane et al., 2013).We have observed that in-
terferon treatment could signiﬁcantly enhanceMxBexpression in Jurkat
cells (Fig. S10B). However, enhancedMxB expression had little effect on
HIV-1 infection when compared to untreated Jurkat cells (Fig. S10A).
The cell type dependent differences in HIV-1 sensitivity to MxB suggest
the potential existence of a co-factor required for MxB mediated HIV-1
restriction.
4. Discussion
Interferon (IFN) is a key component of the innate immune response
to exogenous pathogens. Interferon increases the mRNA levels of
interferon-stimulated genes (ISGs) in vivo which is thought to account
for its antiviral activity. Recent studies have identiﬁed that human
myxovirus resistance protein B, one of the ISG's, contributes to the inhi-
bition of HIV-1 replication by interferon. However, whether HIV-1 could
evolve to counteract against MxB restriction has been undeﬁned. In the
present study, we identiﬁed and characterized a number of capsid var-
iants that render the mutant HIV-1 viruses resistant to the inhibition of
MxB without altering viral ﬁtness. These mutant viruses maintainedc of MxB-viral core binding assay: HIV-1 viruseswere exposed brieﬂy to 0.1% Triton X-100,
ents. (B) and (C) The individual gradient fractions representing solubleMxB (F1) and core-
and MAp17 were used as controls.
Fig. 5.Diagramof proposedmodels for HIV-1 evasion of the antiviral activity ofMxB.MxB as an endogenous lentiviral infection sensor is located at the nuclear pore. AfterHIV-1 entry,MxB
recognizes and binds to the core, which allows the attachment of a MxB cofactor to bind to the complex, thereby inhibiting viral infection. HIV-2 or HIV-1 with certain CA surface residue
mutations avoid the putative MxB cofactor binding and are resistant to MxB mediated viral restriction.
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lines aswell as in primarymacrophages (Fig. 1). Furthermore, likewild-
type virus, they do not trigger type I interferon production during infec-
tion of primary macrophages (Fig. 1h). This is in sharp contrast to the
HIV-1 mutant (G89V) that lost the ability to bind CyPA and became re-
sistant to MxB inhibition but could not prevent interferon production
(Fig. 1h).
The capsid mutations that could render HIV-1 less sensitive to MxB
restriction are detected among primary HIV-1 isolates. Of particular in-
terest is the ﬁnding that MxB resistant variants containing A116 are
most commonly found in the Clade C HIV-1 viruses that are the most
rapidly expanding clade throughout the world. Furthermore, as the
HIV-1 epidemic spreads in China, there is a clear positive selection for
those MxB resistance variants that do not alter viral ﬁtness. These ﬁnd-
ings support a critical role for MxB as a selective force during HIV-1
transmission and evolution. It is not clear why the A116 mutation that
has become predominant in subtype C HIV-1 viruses has not attained
the same dominance in other HIV-1 subtypes such as A, B, and D,
which still primarily carry G116. One possibility is that these HIV-1 sub-
types do not encounterMxB inhibition duringHIV-1 transmissionwhen
compared to subtype C HIV-1. Alternatively, A116 in CA is less ﬁt than
G116 in certain HIV-1 subtypes and is only selected when they encoun-
terMXB selection. Another possibility is that HIV-1 subtypes A, B, and D
use other strategies to overcome MxB restriction.
MxB targets HIV-1 capsid to mediate its anti-viral function.We have
observed that HIV-1 resistant variants maintained the ability to be rec-
ognized by MxB, suggesting the existence of MxB co-factor(s) required
forMxBmediated viral restriction. Consistent with this idea, Jurkat cells
express high level of endogenous MxB proteins after interferon treat-
ment (Fig. S10). However, interferon induced MxB expression did not
alter HIV-1 infectivity in these Jurkat cells compared to the untreated
Jurkat cells (Fig. S10). It has been reported that U937 cells express
MxB, but this expression has limited impact on HIV-1 infection (Kane
et al., 2013). CypA has been reported to be a critical factor for MxB me-
diated HIV-1 restriction. We have observed that addition of CypA bind-
ing to HIV-2 capsid did not alter HIV-2 sensitivity to MxB (Fig. S9).
Factor(s) in addition to CypA may be required for MxB mediated HIV-
1 restriction. Interestingly, the three MxB-resistant HIV-1 capsidvariants are all located on the raised surface region formed by two sub-
units of the capsid hexamer (Fig. S11), suggesting that these sites could
inﬂuence the putative MxB cofactor binding but may not alter intrinsic
features of the viral core (Fig. 5). Identiﬁcation of the critical role of
these HIV-1 capsid mutations in overcoming a host restriction factor
may provide opportunities for the development of therapeutic
interventions.
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